Latest Breaking News On - Pyxis oncology - Page 11 : comparemela.com

BioAtla, Inc (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Quarter 2023 Earnings Call. At this time, all lines are in a listen-only mode.

Rick waldronSheri lydickRichard waldronBruce waldronIpsen bioscienceEric sieversKaveri pohlmanBrian chengBristol myers squibbBruce mackleHead of clinical developmentBioatla incHead of clinical development at pyxis oncologyCall transcript novemberBioatla third quarterJay short

Hoping to pave a longer runway, Pyxis cuts staff, reprioritizes

Hoping to pave a longer runway, Pyxis cuts staff, reprioritizes
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Klara sullivanPyxis oncologyBig pharmas

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

PYX-201 Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 : Phase 1 trial now focusing on NSCLC and other tumor types; data expected 2H 2024. Cash runway.

United statesPam connealyLaras sullivanApexigen incCompany quarterly report on formPyxis oncology incChief executive officerPyxis oncologyPrivate securities litigation reform actQuarterly reportConsolidated statements

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPam connealyLaras sullivanApexigen incPyxis oncology incCompany quarterly report on formOncology announces initiativesPrioritize leadReports financial resultsProvides corporateChief executive officerPyxis oncologyPrivate securities litigation reform actQuarterly reportConsolidated statements

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

07.11.2023 - PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 (a fully human immunotherapy .

United statesPam connealyLaras sullivanCompany quarterly report on formApexigen incPyxis oncology incChief executive officerPyxis oncologyPrivate securities litigation reform actQuarterly reportConsolidated statements